Bio-Rad Laboratories, Inc. (BIO) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 1 Strong Buy, 7 Buy, 6 Hold.
The consensus price target is $327.50 (low: $320.00, high: $335.00), representing an upside of 12.1% from the current price $292.23.
Analysts estimate Earnings Per Share (EPS) of $10.28 and revenue of $2.58B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-65.36 vs est $10.28 (missed -735.6%). 2025: actual $27.87 vs est $10.12 (beat +175.5%). Analyst accuracy: 10%.
BIO Stock — 12-Month Price Forecast
$327.50
▲ +12.07% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Bio-Rad Laboratories, Inc., the average price target is $327.50, with a high forecast of $335.00, and a low forecast of $320.00.
The average price target represents a +12.07% change from the last price of $292.23.
Highest Price Target
$335.00
Average Price Target
$327.50
Lowest Price Target
$320.00
BIO Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to Bio-Rad Laboratories, Inc. in the past 3 months
EPS Estimates — BIO
10%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$65.36
vs Est $10.28
▼ 115.7% off
2025
Actual $27.87
vs Est $10.12
▲ 63.7% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — BIO
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $2.567B
vs Est $2.578B
▼ 0.5% off
2025
Actual $2.583B
vs Est $2.579B
▲ 0.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
